Eureka Nanobioengineering

Eureka Nanobioengineering is an Argentina-based biotechnology company that has developed the NBMods platform, a programmable protein-assembly system designed to create multifunctional nanobiodevices. By utilizing rational protein design, the company engineers viral proteins into self-assembling, homogeneous, monodisperse scaffolds. These scaffolds can be fused with various functional cargoes—such as antigens, adjuvants, or reporters—enabling a modular, Lego-like approach to build precise, multivalent particles with controlled topology and orientation. This architecture allows for combinatorial design, facilitating the creation of customized, stable, and cost-effective biological tools while bypassing traditional manufacturing bottlenecks.

The company operates a B2B model, providing platform access for co-development, licensing of lead assets, and strategic partnerships with pharmaceutical firms to accelerate development pipelines. Their technology addresses needs across detection, prevention, and treatment, with current applications including diagnostics, next-generation vaccine platforms, and immunotherapies for neurodegenerative diseases. By enabling rapid, on-demand formulation updates, Eureka seeks to improve global health outcomes through a One Health approach, providing scalable and adaptable solutions for infectious diseases and pandemic preparedness.